Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI). NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stukaite-Ruibiene, Egle, Norvilas, Rimvydas, Dirse, Vaidas, Stankeviciene, Sigita, Vaitkeviciene, Goda Elizabeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510372/
https://www.ncbi.nlm.nih.gov/pubmed/36172171
http://dx.doi.org/10.3389/pore.2022.1610570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510372/
https://www.ncbi.nlm.nih.gov/pubmed/36172171
http://dx.doi.org/10.3389/pore.2022.1610570

Ejemplares similares